Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company one of the top performers in the S&P 500.

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...

The company's pending vaccine approvals could help the stock continue its rise.

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, ...

We’re maintaining our $227 fair value estimate for Moderna following positive long-term data that we believe supports the value of the firm’s mRNA technology as a novel cancer treatment. Moderna and ...

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...